

insert therefor -- XIII and XIV --; line 20, delete "XIV and XV" and insert therefor -- XII and XIV --.

On page 136, line 26, delete "where" and insert therefor -- were --; line 27, delete "where monitored and where" and insert therefor -- were monitored and were --; line 28, delete "where" and insert therefor -- were --.

On page 137, line 1, delete "where" and insert therefor -- were --; line 5, delete "where" and insert therefor -- were --; line 6, delete "mucopus" and insert therefor -- mucous --; line 6, delete "where" and insert therefor -- were --.

On page 141, line 23, delete "ware" and insert therefor -- were --.

On page 148, line 8, delete "(B)" and insert therefor -- Figures 33C-H --.

In the Claims:

Please cancel Claims 106, 107 and 109.

Please amend Claims 119-123 as follows:

119. (Amended) [The method of Claim 106 wherein] A method of treating TNF α -mediated disease, other than disease resulting from infection, in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises the non-human variable region [comprises] comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.: 5.

120. (Amended) [The method of Claim 113] A method of treating TNF α -mediated disease, other than disease resulting from infection, in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises

the non-human variable region [comprises] comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.: 5 and an IgG1 human constant region.

8 *6*
121. (Amended) The method of Claim [106] 119 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.: 2 and SEQ ID NO.: 4.

F1 *7* *9*
122. (Amended) The method of Claim [113] 120 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.: 2 and SEQ ID NO.: 4.

123. (Amended) A method of treating TNF α -mediated disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2 and said disease is selected from the group consisting of immune and autoimmune pathologies, and inflammatory diseases [, neurodegenerative diseases, malignant pathologies, and alcohol-induced hepatitis].

Sub H

REMARKS

Claim Amendments

Claims 106, 107, and 109 have been cancelled in an effort to advance prosecution. Claims 119-123 have been amended. The amendments are made for the purpose of more clearly delineating that which Applicants regard as their invention. No new matter has been added.